INTRAVENOUS RITUXIMAB COMBINED WITH TEMOZOLOMIDE AS A SECOND-LINE THERAPY FOR CD20-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANT LYMPHOMA

被引：0
|
作者：
Matsuno, Akira [1 ]
Murakami, Mineko [1 ]
Nakaguchi, Hiroshi [1 ]
Sasaki, Mitsuyoshi [1 ]
Uno, Takeshi [1 ]
Ide, Fuyuaki [1 ]
Tanaka, Hideki [1 ]
Fujimaki, Takamitsu [2 ]
机构：
[1] Teikyo Univ, Chiba Med Ctr, Dept Neurosurg, Chiba, Japan
[2] Saitama Med Univ, Dept Neurosurg, Saitama, Japan
来源：
NEURO-ONCOLOGY | 2009年 / 11卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：970 / 970
页数：1
相关论文
共 50 条
  • [1] Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma
    Wada-Shimosato, Yuko
    Ikeda, Junji
    Tsujimoto, Shin-ichi
    Sasaki, Koji
    Yanagimachi, Masakatsu
    Kajiwara, Ryosuke
    Shiba, Norio
    Murata, Hidetoshi
    Kawahara, Nobutaka
    Yamanaka, Shoji
    Tanoshima, Reo
    Ito, Shuichi
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2019, 41 (07) : 571 - 573
  • [2] Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma
    Hai-Tao Zhao
    Jing Chen
    Sheng-bin Shi
    Jing Tian
    Rong-Jie Tao
    [J]. Medical Oncology, 2015, 32
  • [3] Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule
    M. Santisteban
    Y. Nieto
    S. De la Cruz
    J. Aristu
    J. L. Zubieta
    O. Fernández Hidalgo
    [J]. Clinical and Translational Oncology, 2007, 9 : 465 - 467
  • [4] Pemetrexed plus rituximab as second-line treatment for primary central nervous system lymphoma
    Zhao, Hai-Tao
    Chen, Jing
    Shi, Sheng-bin
    Tian, Jing
    Tao, Rong-Jie
    [J]. MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 5
  • [5] Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule
    Santisteban, M.
    Nieto, Y.
    De la Cruz, S.
    Aristu, J.
    Zubieta, J. L.
    Fernandez Hidalgo, O.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (07): : 465 - 467
  • [6] Second-line treatment for primary central nervous system lymphoma
    M Reni
    A J M Ferreri
    E Villa
    [J]. British Journal of Cancer, 1999, 79 : 530 - 534
  • [7] CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab
    Yan, Min
    Dong, Zhaoming
    Zhao, Frank
    Chauncey, Thomas
    Deauna-Limayo, Delva
    Wang-Rodriguez, Jessica
    Liu, Dayu
    Wang, Huan-You
    Pilz, Renate
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (01) : 77 - 80
  • [8] Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
    Murakami, Mineko
    Fujimaki, Takamitsu
    Asano, Shuichiro
    Nakaguchi, Hiroshi
    Yamada, Shoko M.
    Hoya, Katsumi
    Yamazaki, Kazuto
    Ishida, Yasuo
    Matsuno, Akira
    [J]. YONSEI MEDICAL JOURNAL, 2011, 52 (06) : 1031 - 1034
  • [9] INTRAPLEURAL RITUXIMAB FOR THE TREATMENT OF MALIGNANT PLEURAL EFFUSION DUE TO CD20-POSITIVE LYMPHOMA
    Law, M. F.
    Chan, H. N.
    Lai, H. K.
    Ha, C. Y.
    Ng, C.
    Yeung, Y. M.
    Yip, S. F.
    [J]. HAEMATOLOGICA, 2015, 100 : 405 - 405
  • [10] Central nervous system involvement in CD20-positive primary peripheral T-cell lymphoma, not otherwise specified
    Katayama, Y.
    Saitou, K.
    Yokote, H.
    Toru, S.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 388 - 389
12345